Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Source: Investing News Network
2026-03-05 10:52:29 ET
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.
The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims that Moderna’s vaccines infringed patents related to lipid nanoparticle (LNP) delivery technology.
For further details see:
Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Pfizer Inc.
NASDAQ: PFE
PFE Trading
1.73% G/L:
$27.155 Last:
18,083,915 Volume:
$26.82 Open:
PFE Latest News
PFE Stock Data
$156,612,814,520
5,628,850,476
0.02%
1712
N/A
Pharmaceuticals
Healthcare
US
New York
